James George Chopas - 30 Aug 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
VP, Corporate Controller / Chief Accounting Officer
Signature
/s/ David Watson, attorney-in-fact for James Chopas
Issuer symbol
APLS
Transactions as of
30 Aug 2021
Net transactions value
$0
Form type
4
Filing time
01 Sep 2021, 16:34:21 UTC
Next filing
27 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +7,600 $0.000000 7,600 30 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (right to buy) Award $0 +21,750 $0.000000 21,750 30 Aug 2021 Common Stock 21,750 $65.41 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are issuable upon vesting of restricted stock units that each represent a contingent right to receive one share of APLS common stock. The restricted stock units vest as to 25% of the shares underlying the award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the award annually until the fourth anniversary of the grant date, subject to continued service.
F2 This option was granted on August 30, 2021 and vests as to 25% of the shares underlying the option on the first anniversary of the grant date and thereafter as to 1/48th of the shares underlying the option monthly until the fourth anniversary of the grant date, subject to continued service.

Remarks:

VP, Corporate Controller / Chief Accounting Officer